China's Venus Medtech buys Israeli co Cardiovalve

Amir Gross  credit: Shlomi Yosef
Amir Gross credit: Shlomi Yosef

Venus Medtech will pay $150 million immediately and a further $150 million dependent on reaching regulatory milestones.

Israeli heart valve treatment company Cardiovalve has announced an agreement for the sale of the company to Venus Medtech (Hangzhou) Inc., a Chinese structural heart disease treatment company. Venus Medtech will pay $150 million immediately and a further $150 million dependent on reaching regulatory milestones, among them the CE mark and approval for marketing in China. The agreement commits the buyer to invest another $100 million in Cardiovalve, in accordance with a detailed plan drawn up by the two sides.

Cardiovalve was founded in Israel in 2010 by its CEO Amir Gross. Gross was also the founder of Valtech Cardio, which he led until its acquisition in 2017 by US medical equipment company Edwards Lifesciences in a deal involving an advance payment of $340 million with a potential consideration totaling $1 billion. It is estimated that, so far, Valtech Cardio's investors have received $500-600 million.

When Valtech Cardio was sold, Edwards Lifesciences was interested in only part of its activity, system for treating the mitral valve in the heart. Another of Valtech Cardio's products, a system for replacing the same valve, remained with the company's shareholders. The investors and the team led by Gross decided to continue with the remaining activity, which is how Cardiovalve (formerly Mitraltech Ltd.) was born. $20 million from the proceeds of the exit were invested in the company, plus a further $20 million at a later stage by the same investors, so that the investor group gained twice over.

The main gainer is Peregrine Ventures. Valtech grew up in its Incentive technology incubator. Peregrine identified the need for its product through its familiarity with the major medical device companies, and brought about the founding of the company headed by Gross. Other substantial investors are Larry Best, formerly CFO of Boston Scientific, who has invested in several companies in Israel, US venture capital firm NGN Capital, European fund OXO, and GlenRock. Gross himself is not only CEO but also an investor out of the proceeds of the Valtech exit.

History is repeating itself," Gross told "Globes". "In 2015, we signed a deal to sell Valtech Cardio to American company Heartware for $860 million, but in 2016 the deal fell apart. On the day that happened, we were already receiving phone calls from other potential buyers, among them Edwards, and at the end of a very intensive year, the deal was signed."

Gross says that Edwards had an option to buy the new activity, that of Cardiovalve, as well. "They chose instead to go forward with a parallel product of their own. They notified us that they would not be exercising the option just before the coronavirus pandemic started, and two weeks later we received a call from Venus. We received calls from several other potential buyers as well.

"But that happened in March, and straight after that the whole world, and China in particular, was hit by the coronavirus storm, so everything slowly and we disappeared from each other a bit, but last May the talks were renewed. During that period we managed to raise the value of the company, as our product had been implanted in some twenty patients for each of our indications, replacement of the mitral valve and replacement of the tricuspid valve. Had it not been for Covid-19, we would certainly have done at least double that. And in July, it was clear to me that it was a done deal."

Venus Medtech is a Chinese medical devices company that deals, like Edwards, in the whole area of structural treatments of the heart. "It's a giant Chinese company, number two in China in heart medical devices and number one in the valves market, of which it holds 80%. They're like the Edwards of China," Gross says. Venus Medtech is traded on the Hong Kong Stock Exchange with a market cap of $1.6 billion.

Can the Chinese market be as profitable for a product like this as the US market?

"Certainly. The perception that the Chinese market is poor in relation to the US market is irrelevant to medical devices of this kind. In China there are a billion people, of whom about 250 million are wealthy. In the US, there are 330 million people, and they are by no means all wealthy. The global mitral valve market is estimated at $8 billion, or which $3.3 billion is in China, $2.6 billion in the US, and $2.5 billion in Europe. The market for tricuspid valve replacement is estimated at $2 billion, or which $0.9 billion in in China, $0.2 billion is in Europe, and $0.3 billion is in the US. Incidentally, Venus Medtech also operates outside China, in the US, Europe and Asia."

Where do you go from here? Will there be a third incarnation?

"I'm going to stay with Venus, and we're going to conquer the world. I committed to three years, and in my mind to much more. I'll be in charge of innovation at Venus."

Published by Globes, Israel business news - en.globes.co.il - on December 8, 2021.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2021.

Amir Gross  credit: Shlomi Yosef
Amir Gross credit: Shlomi Yosef
Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018